Day 1 - Wednesday, 13 September 2017
Meeting category
Date(s)
13 Sep 2017 - 14 Sep 2017
Location
Madrid,
Spain
Organizer
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Related Enduring Materials
Enduring Materials
-
Opening Lecture: Inter- and intravariability in PK
Session 1: PK of Monoclonal Antibodies -
Chairs
Etienne Chatelut, PharmD, PhD
Institut Universitaire du Cancer Toulouse - Oncopole, France
Howard Gurney, MBBS, FRACP
Westmead Hospital, Australia
ADA-formation and its effect on Mab PK
PK and PKPD considerations for dose selection in the development of pembrolizumab
Session 2: TDM for Targeted Therapies -
Chairs
Michelle Rudek, PharmD, PhD
Johns Hopkins University, USA
Maria-Jesus Garrido, PhD
University of Navarra, Spain
Model-based TDM for oncology drugs
Physiologically based PK model vs. Population PK approach during drug development
Session 3: Drug-Drug Interaction -
Chairs
Lena Friberg, PhD
Uppsala University, Sweden
Stijn Koolen, PharmD, PhD
Erasmus MC Cancer Institute, Netherlands
Clinical case discussions
Clinical case discussions
Clinical case discussions (presentation is not available)
Guillemette Benoist, MSc
Radboud University Medical Centre, the Netherlands
Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma
Evaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposure
Session 4: Drug Transporters and Epigenetic -
Chairs
Nielka van Erp, PharmD, PhD
Radboud University Medical Centre, the Netherlands
Michelle Rudek, PharmD, PhD
Johns Hopkins University, USA
Drug transporters as modulators of chemotherapy toxicity (presentation is not available)
Alex Sparreboom, PhD
The Ohio State University, USA
DNA-Methylation of ADME genes (presentation is not available)
Matthias Schwab, MD
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer
Quantification of anti-drug-antibodies impact on drug exposure of a new anti-cancer drug using a population PK modeling approach (presentation is not available)
Candice Jamois, Switzerland
Abstract #O_04
Day 2 - Thursday, 14 September 2017
Session 5: Optimal Study Design -
Chairs
Lena Friberg, PhD
Uppsala University, Sweden
Maria-Jesus Garrido, PhD
University of Navarra, Spain
Optimal design – potential application in oncology drug development and clinical practice
Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
The use of mathematical modeling to predict efficacious doses and schedules from pre-clinical data for the ATM inhibitor AZD0156 in combination with irinotecan (presentation is not available)
Michael Davies, UK
Abstract #O_06
Session 6: Cancer Drug Regulation -
Chairs
Etienne Chatelut, PharmD, PhD
Institut Universitaire du Cancer Toulouse - Oncopole, France
Treatment optimisation in cancer drug regulation, adults /paediatrics (presentation is not available)
Lucas Moreno, MD, PhD
Hospital Infantil Universitario Niño Jesús, Spain
Drug-exposure response models for safety and efficacy in the use of doxorubicin plus lurbinectedin (presentation is not available)
Carlos Fernandez, Spain
Abstract #O_07
Assessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokinetics
The impact of dose and simultaneous use of acid reducing agents on the effectiveness of vemurafenib in metastatic BRAF V600 mutated melanoma: a retrospective cohort study (presentation is not available)
Nielka van Erp, the Netherlands
Abstract #O_09
Development of an online drug-drug interaction resource to support prescribing of oncolytics (presentation is not available)
Nienke Lankheet, the Netherlands
Abstract #O_10
Overview
Welcome
We are pleased to look back on a very successful 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs, held in Madrid, Spain, on 19th and 20th September, 2017.
45 delegates attended the workshop and the Organizing committee and organizers would like to thank the speakers, chairs and all participants for their contribution to this meeting! In particular we would like to thank our workshop sponsors. Without their financial contribution this workshop would not have been made possible.
We look forward to seeing you again next year at the 3rd International Workshop on Clinical Pharmacology of Anticancer Drugs, scheduled on the 8th and 9th November 2018, in Amsterdam, the Netherlands.
The Organizing Committee
Support
